ProSomnus Prevails in Intellectual Property Enforcement Action

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire ProSomnus Prevails in Intellectual Property Enforcement ActionAuthor of the article:Federal Court Awards Damages, Fees and Costs Following ProSomnus Intellectual Property Enforcement ActionTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountSAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (“ProSomnus”), the pioneer and global leader in Smart Sleep Medicine™, today announced a significant victory in its intellectual property enforcement action, reinforcing the Company’s commitment to protecting the innovations, technologies, and proprietary assets that support advances in sleep medicine. The United States District Court for the Southern District of Florida adopted in full the Magistrate Judge’s Report and Recommendation, awarding ProSomnus $100,000 in damages against each of the four Defendants, together with more than $80,000 in attorneys’ fees and costs. The Court’s decision concludes a successful intellectual property enforcement action brought by ProSomnus to protect assets developed through years of investment in research, product development, clinical evidence generation, manufacturing, and commercialization. Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againIntellectual property protection plays a critical role in healthcare innovation. Developing new medical technologies requires substantial investments in research, engineering, clinical evidence generation, regulatory compliance, quality systems, provider education, manufacturing, and commercialization. ProSomnus believes that patients, providers, and payers are best served when companies compete through innovation, clinical evidence, product quality, and patient outcomes rather than through the unauthorized use of another company’s intellectual property. Competition based on infringement and misappropriation undermines the incentives that drive investment in new technologies, clinical research, and healthcare innovation. “Protecting intellectual property is not simply about protecting a company. It is about protecting patients who ultimately benefit from it,” said Len Liptak, Founder and Chief Executive Officer of ProSomnus. “Healthcare innovation requires substantial investments in research, engineering, clinical evidence generation, regulatory compliance, quality systems, and provider education. Intellectual property theft, misuse, and infringement undermine those investments and weaken the incentives that drive medical innovation. Patients benefit when innovators are rewarded for creating better solutions. Innovation suffers when others seek to benefit from investments they did not make. ProSomnus will continue to actively protect and enforce its intellectual property rights because doing so helps ensure that patients, providers, and payers continue to benefit from meaningful advances in sleep medicine.” “This outcome reflects not only a legal victory, but a commitment to the principle that companies must compete through their own innovation, not through the misappropriation of a competitor’s proprietary assets,” said Patricia Dodson, legal counsel for ProSomnus with Lippes Mathias LLP. This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.The outcome reinforces ProSomnus’s commitment to protecting its innovations, technologies, brands, know-how, trade secrets, and other proprietary assets. The Company intends to continue strengthening its intellectual property portfolio and, when necessary, pursuing appropriate legal remedies to protect innovations that create value for patients, providers, healthcare systems, and payers. ProSomnus believes that robust intellectual property protection promotes fair competition, encourages continued investment in innovation, and advances the development of technologies that improve patient outcomes.About ProSomnus Sleep TechnologiesProSomnus is the pioneer and global leader in Smart Sleep Medicine™, delivering precision, non-CPAP Oral Appliance Therapy (OAT) for Obstructive Sleep Apnea (OSA), with integrated multi-night physiologic monitoring enabled by its RPMO2 platform. A serious medical disease affecting over 1 billion people worldwide, OSA is linked to life-threatening comorbidities including heart failure, stroke, and type 2 diabetes.By integrating precision-engineered intraoral medical devices with advanced Remote Physiologic Monitoring (RPM) and data-driven diagnostics, ProSomnus is redefining the standard of care. Our platform is designed to provide continuous, nightly clinical insights that ensure superior adherence and validated patient outcomes. Non-invasive and patient-preferred, ProSomnus devices have demonstrated exceptional efficacy and safety across a rigorous and growing body of clinical evidence. ProSomnus precision devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, and TRICARE, representing over 200 million covered lives globally. To learn more or find a provider near you, visit www.ProSomnus.com.Media ContactsHeather WhalenHWhalen@ProSomnus.comNotice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.